The ongoing Phase II clinical trial NCT06518837 aims to evaluate the role of tirzepatide, a dual GLP-1 and Gastric Inhibitory Polypeptide (GIP) receptor agonist, in patients with HR+HER2- breast cancer receiving adjuvant treatment. This evidence concerns the gene ERBB2 and breast carcinoma.